


30



3000-1642

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>		Application Number	10/035,832
		Filing Date	December 26, 2001
		First Named Inventor	David W. MORRIS
		Art Unit	1642
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	8 + 14 Refs.	Attorney Docket Number	529452000120

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 (2 pages in duplicate) 2. References (14) 3. Return receipt postcard
<div style="border: 1px solid black; padding: 5px;">Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	MORRISON & FOERSTER LLP Shantanu Basu - 43,318	25226
Signature		
Date	October 27, 2003	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: <u>October 27, 2003</u>	Signature: <u>Martina Placid</u> (Martina Placid)



PATENT
Docket No. 529452000120

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on October 27, 2003

Martina Placid
Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David W. MORRIS and
Eric K. ENGELHARD

Serial No.: 10/035,832

Filing Date: December 26, 2001

For: NOVEL COMPOSITIONS AND
METHODS FOR CANCER

Examiner: Not Yet Assigned

Group Art Unit: 1642

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 529452000120. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: October 27, 2003

Respectfully submitted,

By: 
Shantanu Basu
Registration No. 43,318

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5995
Facsimile: (650) 494-0792



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 529452000120	Application Number 10/035,832
	Applicant David W. MORRIS and Eric K. ENGELHARD	
	Filing Date December 26, 2001	Group Art Unit 1642
	Mailing Date October 27, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	01/30/2003	WO 03/008583	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	2.	Berns, A. (Date unknown). "Table A: Retroviral Insertion Sites in EμMyc and EμMyc; Pim1 ^{-/-} Pim 2 ^{-/-} Lymphomas ^a ," published in the advance online issue of <i>Nature Genetics</i> , 13 pages total.
	3.	Berns, A. (Date unknown). "Web Fig A," describing PIM protein actions, published in the advance online issue of the <i>Nature Genetics</i> , 1 page total.
	4.	Campbell, A. M. (1984). "The Production and Characterization of Rodent and Human Hybridomas," Chapter 1 In <i>Monoclonal Antibody Technology</i> . Burdon, R. H and van Knippenberg, P. H., eds, Elsevier, pp.1-32.
	5.	Database GenCore on STN, Accession NO. U52152, Schoots et al. "Cloning of Four Inwardly Rectifying Potassium Channels from Human," Direction Submission March 25, 1996 amino Acid and Nucleic acid Sequences
	6.	Database GenCore on STN, on Accession Number AF275818, Yang et al. 23 July 2000. "A Family of Novel PR- Domain (PRDM) Genes as Candidate Tumor Suppressors"
	7.	Hunter, W. M. and Greenwood, F. C. (1962). "Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity," <i>Nature</i> 194:495-496.
	8.	Jiang, G-L et al. (2000). "The Yin-Yang of PR-Domain Family Genes in Tumorigenesis," <i>Histol. Histopathol.</i> 15(1):109-117.
	9.	Lohuizen, V. (Date unknown). "Web Table A," describing genomic positions insertion site sequences analyzed against the Celera Mouse Genome Database (CMGD Release 12), published in the advance online issue of <i>Nature Genetics</i> , 9 pages total.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000120

Application Number 10/035,832

Applicant

David W. MORRIS and Eric K. ENGELHARD

Filing Date December 26, 2001

Group Art Unit 1642

Mailing Date October 27, 2003

- | | |
|-----|--|
| 10. | Lohuizen, V. (Date unknown). "Web Table B," describing Genomic positions of insertion site sequences analyzed against the Ensemble Mouse Genome Database (February 2002 freeze), published in the advance online issue of <i>Nature Genetics</i> , 12 pages total. |
| 11. | Lohuizen, V. (Date unknown). "Web Table C," listing GenBank Accession Numbers, published in the advance online issue of <i>Nature Genetics</i> , 11 pages total. |
| 12. | Sawai, H. et al. (1984). "Synthesis and Properties of Oligoadenylic Acids Containing 2'-5' Phosphoramidate Linkage," <i>Chem. Lett.</i> pgs. 805-808. |
| 13. | Schoots, O. et al. (1999). "Co-Expression of Human Kir3 Subunits Can Yield Channels with Different Functional Properties," <i>Cell Signal</i> 11(12):871-883. |
| 14. | Skinner, R. H. et al. (1991). "Use of the Glu-Glu-Phe C-Terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant <i>Ras</i> GTPase-Activating Proteins," <i>J. Biol. Chem.</i> 266(22):14163-14166. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.